Introduction La France présente l'une des couvertures vaccinales HPV les plus faibles d'Europe, bien en deçà des objectifs de l'OMS. Pourtant les HPV sont à l'origine de cancers pour lesquels un vaccin efficace existe. En 2023, un programme national de vaccination en milieu scolaire ciblant les élèves de cinquième a été mis en place, nécessitant une autorisation signée par les deux parents (digitale ou papier). L'obtention de cette double autorisation parentale, étape incontournable du dispositif, peut constituer un frein à la vaccination. Cette étude analyse les facteurs associés au dépôt des autorisations parentales dans une académie française comprenant 358 collèges. Matériels et méthodes Un schéma mixte convergent parallèle a été utilisé pour examiner les déterminants opérationnels, institutionnels et comportementaux du dépôt des autorisations parentales. Un échantillon raisonné de 30 collèges a été constitué reflétant la diversité régionale; 17 collèges ont participé via un questionnaire en ligne auto-administré. Les données quantitatives ont été analysées par des statistiques descriptives. Les collèges ont été catégorisés en deux groupes selon le taux de dépôt : performants (≥25 %) et moins performants (<25 %). Parallèlement, 12 répondants ont participé à des entretiens téléphoniques semi-directifs, les verbatims retranscrits et analysés selon les critères COREQ. Les résultats issus des deux volets ont été intégrés lors de l'analyse. L'interprétation a été guidée par les cadres théoriques NASSS framework, le Health Belief Model et la théorie de la Diffusion de l'Innovation. Résultats Les taux de dépôt varient fortement selon les collèges et sont influencés par les ressources institutionnelles, la coordination et les pratiques de communication. Les collèges les plus performants sont souvent de petite taille, situés en zones rurales et mobilisent davantage de personnels. Les infirmières scolaires jouent un rôle central: l'infirmière est référente de la campagne dans 70,6 % (n=12) des collèges les plus performants et 28,6 % (n=2) des collèges les moins performants ne disposaient d'aucune infirmière. Certains collèges jugent que les modalités numériques de dépôt ne sont pas adaptées à certaines familles. Certains collèges performants ont introduit des informations sur la vaccination HPV lors du dépistage infirmier obligatoire en sixième, perçu par les équipes comme un facilitateur clé. Les freins rapportés sont: une littératie en santé limitée, des facteurs culturels ou moraux, ainsi que la perception du jeune lié à l'âge des élèves de cinquième. Un contact anticipé avec les parents et une coordination interne au niveau de l'établissement émergent comme facteurs facilitants majeurs. Conclusion Cette étude met en évidence des freins et des leviers dans la mise en oeuvre de la campagne de vaccination HPV en milieu scolaire. L'analyse souligne le rôle central des infirmières scolaires, tandis qu'un faible niveau de littératie en santé et des difficultés liées aux procédures numériques réduisent l'engagement parental. Les résultats montrent également l'intérêt d'impliquer les parents plus tôt, dès la classe de Sixième, afin de renforcer la sensibilisation, la confiance et la communication en amont de l'offre vaccinale. L'étude s'inscrit dans une dynamique régionale plus large avec une progression de 29 points de la couverture vaccinale HPV par rapport à la période pré-campagne, positionnant la région parmi les plus performantes en 2024-2025.
e13617 Background: Cancer is the second leading cause of death in Europe and the primary cause of mortality among individuals under 65 years of age. Despite major advances in oncology, substantial disparities persist across European countries in access to high-quality cancer care, early diagnosis, innovative treatments, and clinical research. Addressing these inequities requires system-level models of care that integrate clinical excellence, research, education, and sustainability. In response, the European Commission launched Europe’s Beating Cancer Plan, under which the European Network of Comprehensive Cancer Centres (EUnetCCC) was established to transform cancer care delivery across Europe. Methods: EUnetCCC is a Joint Action funded by the EU4Health Programme, coordinated by the French National Cancer Institute, involving all 27 European Union Member States and four associated countries. The initiative is structured into nine Work Packages addressing governance, certification, sustainability, quality improvement, research integration, and the implementation of Comprehensive Cancer Networks. A standardized certification framework for Comprehensive Cancer Centres (CCCs) was developed to promote harmonized quality standards, multidisciplinary care, integration of research and clinical practice, and cross-border collaboration. Results: EUnetCCC currently includes 163 partner institutions from 31 countries and aims to ensure that by 2028, at least 90% of eligible cancer patients in Europe will have access to high-quality comprehensive cancer care through a network of at least 100 certified CCCs, with at least one CCC in each Member State. The model facilitates equitable access to quality-assured diagnostics, innovative therapies, clinical trials, and professional training, while strengthening capacity in less-resourced regions. Cross-border collaboration within the network supports patient mobility, shared expertise, and improved care delivery for complex cancer cases. Conclusions: EUnetCCC represents a scalable, system-level model for cancer care delivery that integrates quality, equity, and innovation across diverse healthcare systems. By harmonizing standards and embedding research into routine care, EUnetCCC addresses structural disparities and provides a transferable framework for improving quality and outcomes in cancer care globally.
Abstract Issue The Lancet Commission on “Women, Power, and Cancer” highlighted the underrepresentation of women in leadership roles in cancer research and policy. It recommended actions to ensure equitable access to resources, leadership positions, and research funding, including monitoring “the percentage of funding for oncology research allocated to female principal investigators (PI) or project leaders”. Description of problem In line with a study led in collaboration with the International Cancer Research Partnership (ICRP), the French National Cancer Institute analysed gender‑related data for 3 296 cancer research projects funded between 2008 and 2024. PI gender was estimated using a name‑to‑gender algorithm to assess differences in the number and amount of grants awarded to male and female PIs and to examine changes over time. Results Female PIs submitted 43% of applications and received 39% of grants. Their submissions increased from 31% in 2008 to over 50% in 2024, but the share of funded projects led by women remained stable. Average funding amounts differed (€490 230 for women vs €772 970 for men). Women received 68% of individual fellowships. In 2023, they represented 52% of evaluation committee members. Lessons These results will support the implementation of new initiatives dedicated to gender equality, in line with the national open science policy. These include improving training on gender equality and parity within evaluation committees and developing tools and strategies to increase the inclusion of women and reduce unconscious bias and implementing mentoring programs to support women throughout their scientific careers. Funders are encouraged to collect and publicly report PI gender information of funded research projects, to focus on stopping the “leaky pipeline” of female investigators in cancer research, and to develop and implement strategies to increase equity in review and evaluation processes. Key messages • Female submitting cancer research projects increased from 2008 to 2024, yet the share of projects funded and led by French women has remained largely unchanged over time. • This cancer research analysis with the ICRP offers a benchmark for funder policies, and further analyses should examine whether gendered funding patterns influence research output and equity.
ABSTRACT:FLT3 internal tandem duplications (FLT3-ITD) are major genetic events in acute myeloid leukemia (AML). Although the clinical impact of FLT3-ITD "macroclones" (allelic ratio [AR] ≥0.05) is well established, the significance of low-level FLT3-ITD subclones ("microclones") remains uncertain. We conducted a post hoc analysis of 1733 patients with newly diagnosed AML enrolled in the Backbone Intergroup 1 trial (ClinicalTrials.gov identifier: NCT02416388). Using next-generation sequencing (NGS), we detected FLT3-ITD microclones (AR between 0.0004 and 0.05) in 17.4% of patients without FLT3-ITD macroclones. Microclones and macroclones (low and high AR) were independently associated with increased relapse risk (cause-specific hazard ratio, 1.50 [95% confidence interval (CI), 1.18-1.91]; 1.98 [1.50-2.62]; and 2.33 [1.69-3.22], respectively) after adjustment for age, white blood cell count, other gene mutations, midostaurin treatment, and allogeneic hematopoietic stem cell transplantation. At 2 years, the cumulative incidence of relapse reached 42.5% (95% CI, 37.0-47.9) in patients with macroclones, 45.1% (38.3-51.6) in patients with microclones, and 29.4% (26.6-32.3) in patients without FLT3-ITD. In NPM1-mutated AML, both microclones and macroclones were associated with higher levels of measurable residual disease (MRD) and increased relapse risk, without independent impact on overall survival after adjustment for MRD. An analysis of paired samples further revealed that 41.8% of relapses in patients with FLT3-ITD microclones at diagnosis were associated with a macroclone at relapse. These findings challenge current risk stratification models and support the integration of NGS-based FLT3-ITD detection into the diagnostic and prognostic workflow for AML. Prospective trials addressing the management of patients with FLT3-ITD microclones are warranted, as is their consideration in future European LeukemiaNet guidelines.